The recommended dose of disulfiramab is every 4 weeks, with the option of bimonthly injections after 6 months, and once every 6 months after prolonged injections and stable drug concentrations. The main reason for maintaining a fixed time for drug injection is to maintain an effective and stable drug concentration, which is the only way to control the symptoms. It is recommended to determine the dose and interval of vaccination according to different diseases under the guidance of a doctor. The injection site can be chosen from the upper arm, upper thigh or abdomen for subcutaneous administration. During treatment with disulfiramab, periodic evaluations should be performed to ensure continued patient benefit. Calcium therapy can be combined with calcium and vitamin D supplementation and more sun exposure to promote calcium absorption during the day. Disulfiramab is a bone resorption inhibitor, an osteoporosis-targeted therapeutic agent that targets the osteoclast regulatory pathway. Its main component is a monoclonal antibody to human immunoglobulin G2, which is used for the treatment of bone metastases from giant cell tumors of bone or solid tumors and multiple myeloma that are not surgically resectable, or where surgical resection may result in severe dysfunction, as well as for the treatment of osteoporosis in postmenopausal women and androgen deprivation therapy for men with prostate cancer, and for bone loss due to aromatase inhibitor therapy for breast cancer.